This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 67,394 trials Clear all
Filter by:

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

  • Status Recruiting
    Recruiting
  • Condition Glioblastoma, Gliosarcoma, Malignant Glioma
    Glioblastoma, Gliosarcoma, Malignant Glioma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: TMZ, Drug: ipilimumab 3mg/kg, Drug: Nivolumab, Drug: ipilimumab 1mg/kg

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: TMZ, Drug: ipilimumab 3mg/kg, Drug: Nivolumab, Drug: ipilimumab 1mg/kg

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Brief Summary

Background: Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur. Researchers want to study people with newly diagnosed disease to learn more. Objective: To study people with newly diagnosed GBM or gliosarcoma to look at the changes in immune cells in the blood of those who take ipilimumab and nivolumab, along with temozolomide. Eligibility: Adults ages 18 and older with newly diagnosed GBM or gliosarcoma, who have had surgical removal of their tumor and have completed standard initial chemotherapy and radiation therapy. Design: Participants will be screened with the following: Medical record review Medical history Physical exam Tests to assess their nervous system and their ability to do typical activities Blood tests Tumor assessment. For this, they will have magnetic resonance imaging (MRI). They may get a contrast dye through an intravenous (IV) catheter. The MRI scanner makes noise. They will get earplugs. Electrocardiogram. It measures heart rate and rhythm. They will lie still. Sticky pads will be placed on their chest, arms, and legs. Screening tests will be repeated during the study. Treatment will be given in cycles. Each cycle lasts 4 weeks. Participants will get nivolumab and ipilimumab via IV. They will take temozolomide by mouth. They will keep a pill diary. Participants will fill out surveys about their symptoms. Participants will have follow-up visits about 60 days and 100 days after treatment ends. Then they will be contacted every 6 months for the rest of their life.

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

  • Status Recruiting
    Recruiting
  • Condition Primary Sjögren Syndrome
    Primary Sjögren Syndrome
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Iguratimod, Drug: Placebo

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Iguratimod, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Peking University People's Hospital, Beijing, Beijing, China

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

  • Status Recruiting
    Recruiting
  • Condition Meningococcal Vaccine
    Meningococcal Vaccine
  • Phase Phase 3
    Phase 3
INTERVENTION

Biological: Nimenrix

Eligibility
  • Ages: 76 to 104 Days (Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Nimenrix

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tampere Vaccine Research Clinic, Tampere, Pirkanmaa, Finland

Brief Summary

This study will evaluate the safety and immunogenicity of a single dose of Nimenrix in infants at 3 months of age, followed by a second dose at 12 months of age. Current posology allows for 2 doses of Nimenrix before 6 months of age, where the first dose is administered from 6 weeks onwards with a second dose at least 2 months later, with a booster at 12 months; and in infants from 6 months of age, a single dose at 6 months, with a booster dose at 12 months. This study will provide valuable immunogenicity and safety data for a single dose in healthy infants <6 months of age, followed by the booster at 12 months

Dual MRI for Cardiopulmonary COVID-19 Long Haulers

  • Status Recruiting
    Recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Hyperpolarized 129Xenon gas

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Hyperpolarized 129Xenon gas

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Duke Asthma, Allergy, and Airway Center, Durham, North Carolina, United States

Brief Summary

The next phase of the COVID-19 pandemic is likely to see a surge in an associated chronic cardiopulmonary disease that will challenge health systems. Recovered patients are presenting with persistent dyspnea at the Duke Pulmonary Post-COVID clinic. Evidence is now mounting that recovered patients have significant residual pulmonary disease, while myocardial injury has also been increasingly reported. To optimally care for these patients, Duke Pulmonary study team must comprehensively assess and monitor the changes in cardiopulmonary function and relate the changes to physiologic and quality of life outcomes. The study team will deploy cutting-edge MRI to fully characterize cardiopulmonary function in enrolled 30 subjects (accrual 23 subjects) at time point 60-120 days post recovery and 6-9 months later. Cardiac MRI will assess the myocardial status and right ventricular function, while hyperpolarized 129Xe MRI will provide a 3D assessment of pulmonary ventilation, interstitial barrier integrity, and pulmonary vascular hemodynamics. The overall objective outlined in this study is to demonstrate the feasibility and value of comprehensive longitudinal imaging characterization of cardiopulmonary structure and function in patients recovered from Covid-19.

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

  • Status Recruiting
    Recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: ensovibep, Drug: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ensovibep, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Jasper Summit Research, LLC, Jasper, Alabama, United States

Brief Summary

The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for treating COVID-19 in adult ambulatory patients

Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

  • Status Recruiting
    Recruiting
  • Condition Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Ca...
    Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Ca...
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Futibatinib, Biological: Pembrolizumab, Other: Quality-of-Life Assessment

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Futibatinib, Biological: Pembrolizumab, Other: Quality-of-Life Assessment

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Brief Summary

This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic). Futibatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving futibatinib and pembrolizumab may help treat patients with FGF19 positive liver cancer.

Safety and Efficacy of Sofwave Treatment to Lift Lax Skin

  • Status Recruiting
    Recruiting
  • Condition Skin Laxity
    Skin Laxity
  • Phase Phase 3
    Phase 3
INTERVENTION

Device: Sofwave

Eligibility
  • Ages: 35 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Device: Sofwave

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

SLSS, a Division of Schweiger Dermatology Group Research Office, Hackensack, New Jersey, United States

Brief Summary

Open-label, non-randomized 2 arms prospective, multi-center, self-controlled clinical study with masked evaluation.

Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus

  • Status Recruiting
    Recruiting
  • Condition Status Epilepticus
    Status Epilepticus
  • Phase Phase 4
    Phase 4
INTERVENTION

Drug: intravenous levetireacetam

Eligibility
  • Ages: 2 to 12 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: intravenous levetireacetam

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ayesha Tariq, Lahore, Punjab, Pakistan

Brief Summary

The purpose of studyis to compare the efficacy of phenytoin with levetiracetam for the management of children with status epilepticus.Study performa consists of demographic variables,exclusion criteria,history of epilepsy and efficacy achieved or not.

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

  • Status Recruiting
    Recruiting
  • Condition Effect of Drug, Toxicity, Drug
    Effect of Drug, Toxicity, Drug
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: apatinib

Eligibility
  • Ages: 12 to 70 Years (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: apatinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Peking University Shougang Hospital, Beijing, Beijing, China

Brief Summary

Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse than that of pulmonary lesions. This treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE). We have ever retrospectively compared the activity of apatinib + IE in relapsed or refractory osteosarcoma in two sarcoma centers in China and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + IE demonstrated clinically meaningful antitumor activity and delayed disease progression in patients with recurrent or refractory osteosarcoma after failure of chemotherapy. However to overcome the influence of other interventions on the outcome, we are currently performing a prospective trial to investigate this combination, from which more accurate data on this treatment strategy are expected.

A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis

  • Status Recruiting
    Recruiting
  • Condition Chronic Pulmonary Aspergillosis
    Chronic Pulmonary Aspergillosis
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Itraconazole 200 mg, Drug: Voriconazole 200mg

Eligibility
  • Ages: 13 to 90 Years (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Itraconazole 200 mg, Drug: Voriconazole 200mg

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Inderpaul Singh, Chandigarh, India

Brief Summary

The current initial therapy for CPA is with six months of oral itraconazole. However, the response with six months of therapy has a response rate of 65-70% and has a relapse rate after stopping treatment of up to 50%. Voriconazole is a third-generation azole and a theoretical advantage of lower MICs compared to itraconazole. Also, oral voriconazole has good availability (95%) in fasting state. This is likely to improve the response rate and reduce the chances of relapse of chronic pulmonary aspergillosis. There is no head to head comparison of oral itraconazole with oral voriconazole. In this study we intent to compare the clinical outcomes with six months of therapy with oral itraconazole versus oral voriconazole for management of treatment naïve subjects with chronic pulmonary aspergillosis